Finance Now Available

Contact lenses to provide controlled drug delivery for Glaucoma

11th December 2013

Achieving controlled drug delivery from a contact lens has been a significant challenge in the field of ophthalmology for decades, but researchers from Harvard Medical School and the Massachusetts Eye and Ear department are now a step closer in achieving this.

Designed for the prolonged delivery of Latanoprost, the common drug for the treatment of Glaucoma, the contact lenses are designed to give consistent and sustainable doses of the drug and have been made with FDA-approved materials.

Appearing safe in cell culture and animal studies, this is an encouraging development for the treatment of Glaucoma, the leading cause of irreversible blindness in the world, and will no doubt pave the way for similar treatments.

LaserVision will keep you up to date on more developments on this subject.

Related Information

As Seen On

The Guardian Logo
Laser Eye Surgery UK
The Times Laser Eye Surgery
At Home Magazine
Saga Logo
Surrey Advertiser Logo
laser eye surgery london
National Eye Health Week 2014

LaserVision is recognised by the following leading UK private medical insurers

Laser Eye Treatment Allianz
Aviva Logo
Laser Eye Correction Hospital
Bupa Medical Insurers
Eye Correction Treatment
Healix Logo
Vitality Insurers
WPA Healthcare

Professional Associations

Ziemer
Alcon
Schwind
Oculus
Zeiss
BauschLomb
AMO
Physiol
IPCL
STAAR Surgical
Rayner
AcuFocus
HeidelBerg Engineering
HSUK

Professional Bodies

ESCRS
Royal College of Surgeons Edinburgh
Royal College of Ophthalmologists
UKISCRS
ASCRS
ISRS Logo
CareQuality Commission
Request a ConsultationAttend an Event